Bioanalysis for Biopharmaceuticals Using the Gyrolab™ xP Workstation

The Gyrolab™ xP workstation has significant advantages over conventional ligand-binding assays (LBA), particularly due to automated sample processing and improved reproducibility. This advanced system streamlines technology transfer, reduces issues, and enables rapid method development. With its automated assay workflow, the Gyrolab™ xP workstation substantially shortens overall assay turnaround time, including sample analysis.

In addition to quantifying biopharmaceutical drugs, the Gyrolab™ xP workstation supports the assessment of anti-drug antibodies (ADA), neutralizing antibodies, and biomarkers. This versatility meets your analytical needs at the nonclinical and clinical development stages.

• Increasing Throughput: The Gyrolab™ xP workstation improves sample throughput, providing an approximately fivefold higher daily sample capacity compared to traditional LBA methods (e.g., ~480 samples/day vs. ~100 samples/day).
• Facilitating Technology Transfer: The complete automation system minimizes issues that often occur during method transfer between laboratories.
• Operator Consistency: The system eliminates variability due to analyst-specific technical differences often observed in ligand-binding assays.
• Low Sample Volume Requirement: Reliable quantification is achievable with minimal sample volumes (less than several microliters).
• Rapid Method Development: An analytical method can typically be established within approximately one week.
• Regulatory Compliance: The system runs in compliance with Good Laboratory Practice (GLP) standards.

• Assay Format: Fully automated ELISA (Gyrolab™ xP workstation)
• Software: Gyrolab™ Control Software v7.2.2, Gyrolab™ Evaluation Software v3.4, Gyrolab™ Viewer module
• Sensitivity: Down to the picogram per milliliter (pg/mL) range
• Throughput: Up to 480 samples (in duplicate) per day
• Operation: No manual operation is required except for sample preparation